| Entry |
|
|---|
| Name |
Idarucizumab (USAN/INN);
Idarucizumab (genetical recombination) (JAN);
Praxbind (TN)
|
|---|
| Product |
|
|---|
| Sequence |
(Heavy chain)
QVQLQESGPG LVKPSETLSL TCTVSGFSLT SYIVDWIRQP PGKGLEWIGV IWAGGSTGYN
SALRSRVSIT KDTSKNQFSL KLSSVTAADT AVYYCASAAY YSYYNYDGFA YWGQGTLVTV
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKKV EPKSC
(Light chain)
DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL YTDGKTYLYW FLQRPGQSPR RLIYLVSKLD
SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQSTHFP HTFGGGTKVE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199) |
|---|
| Type |
Peptide |
|---|
| Remark |
| Therapeutic category: | 3399 |
|
|---|
| Efficacy |
Neutralizer (dabigatran) |
|---|
| Comment |
Monoclonal antibody
Reversal of anticoagulant effects of dabigatran [DR: D07082]
|
|---|
| Target |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03AB Antidotes
V03AB37 Idarucizumab
D10741 Idarucizumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D10741 Idarucizumab (USAN/INN); Idarucizumab (genetical recombination) (JAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10741
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10741
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10741
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10741
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
